Metabolism
Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity
Riportato dall'IA Immagine generata dall'IA Verificato
Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.
A seven-day water-only fast triggers major molecular shifts across the body, with the most significant effects emerging only after three days without food. Researchers tracked protein changes in healthy volunteers to map these responses in detail. The findings highlight both potential health benefits and risks of prolonged fasting.
Study identifies how SLIT3 helps brown fat build blood vessels and nerves needed for calorie burning
Riportato dall'IA Verificato
Researchers report that a protein signal called SLIT3 helps brown fat ramp up heat production by coordinating the growth of blood vessels and sympathetic nerves. In experiments using mouse models and human cells and tissue datasets, the team found SLIT3 is cut into two fragments with distinct roles—one linked to vessel growth and the other to nerve expansion—pointing to possible future obesity-treatment strategies aimed at boosting energy expenditure.